Brief: Xenetic Biosciences QTRLY Net Loss Of About $8.9 Mln Versus About $1.8 Mln

Xenetic Biosciences

15/11/2019 15:16

Nov 15 (Reuters) - Xenetic Biosciences Inc  XBIO.O :
    * XENETIC BIOSCIENCES INC QTRLY NET LOSS OF ABOUT $8.9
MILLION
VERSUS ABOUT $1.8 MILLION
    * XENETIC BIOSCIENCES INC - COMPANY RAMPS UP ACTIVITIES TO
EXECUTE
XCART’S PRECLINICAL AND REGULATORY STRATEGY
    * XENETIC BIOSCIENCES INC - CASH RUNWAY EXPECTED TO FUND
COMPANY
THROUGH PRECLINICAL ADVANCEMENTS TOWARDS IND FILING
    * XENETIC BIOSCIENCES INC - ROYALTY STREAM RESULTING FROM
THE
TAKEDA SUBLICENSE EXPECTED TO COMMENCE BY THE END OF 2019
    * XENETIC BIOSCIENCES INC - ENDED Q3 2019 WITH ABOUT $12.0
MILLION
IN CASH AND $11.2 MILLION OF WORKING CAPITAL

Source text: (http://www.sec.gov/Archives/edgar/data/1534525/000168316819003668/0001683168-19-003668-index.htm)
Further company coverage:  XBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))